文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-FAZA PET/CT在肾细胞癌患者淋巴结转移检测中的作用:一项前瞻性先导试验

The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-07-08

这项概念验证2期研究纳入20例肾癌患者,术前行18F-FAZA PET/CT,评估其在肾癌淋巴结转移检测中的作用。最终病理显示淋巴结侵犯率为16%,但无1例pN1患者18F-FAZA PET阳性,原发肿瘤及远处转移灶亦无病理性摄取。

要点

  • 18F-FAZA PET/CT未检出肾细胞癌淋巴结转移及远处转移。
  • 原发肾肿瘤未见病理性18F-FAZA摄取。
  • 研究期间未记录到不良事件。

核心结论

  • 18F-FAZA PET/CT未检出肾细胞癌淋巴结转移及远处转移,原发肾肿瘤亦未见任何摄取。

研究设计与样本

  • 这是一项概念验证2期研究,纳入20例肾癌患者(ClinicalTrials.gov标识符:NCT03955393)。
  • 纳入标准为以下三项之一:临床肿瘤大小>10 cm、术前CT显示临床淋巴结病变证据、临床T4期癌症。
  • 术前静脉注射放射性示踪剂2小时后行18F-FAZA PET/CT,由经验丰富的核医学科医生结合患者病史及所有可用诊断影像进行定性及半定量分析。
  • 所有患者均获取手术标本的组织病理学分析。

主要发现

  • 14/19(74%)患者最终病理为非器官局限性肾细胞癌(pT3或pT4)。
  • 切除淋巴结中位数为12枚(IQR 7-15)。
  • 淋巴结侵犯率为16%。
  • 无1例pN1患者显示18F-FAZA PET阳性,提示病灶无缺氧行为。
  • 原发肿瘤及远处转移灶均无病理性18F-FAZA摄取。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The accurate detection of nodal invasion is an unmet need in the clinical staging of renal cancer. Positron emission tomography (PET) with 18F-fluoroazomycin arabinoside (18F-FAZA), a hypoxia specific tracer, is a non-invasive imaging method that detects tumour hypoxia. The aim of this work was to evaluate the role of 18F-FAZA PET/CT in the identification of lymph node metastases in renal cancer. METHODS: A proof-of-concept phase 2 study including 20 kidney cancer patients ( ClinicalTrials.gov Identifier: NCT03955393) was conducted. Inclusion criteria were one or more of the following three criteria: (1) clinical tumour size > 10 cm, (2) evidence of clinical lymphadenopathies at preoperative CT scan and (3) clinical T4 cancer. Before surgery, 18F-FAZA PET/CT was performed, 2 h after the intravenous injection of the radiotracer. An experienced nuclear medicine physician, aware of patient's history and of all available diagnostic imaging, performed a qualitative and semi-quantitative analysis on 18F-FAZA images. Histopathological analysis was obtained in all patients on surgical specimen. RESULTS: Fourteen/19 (74%) patients had a non-organ confined renal cell carcinoma (RCC) at final pathology (either pT3 or pT4). Median number of nodes removed was 12 (IQR 7-15). The rate of lymph node invasion was 16%. No patient with pN1 disease showed positive 18F-FAZA PET, thus suggesting the non-hypoxic behaviour of the lesions. In addition, neither primary tumour nor distant metastases presented a pathological 18F-FAZA uptake. No adverse events were recorded during the study. CONCLUSIONS: 18F-FAZA PET/CT scan did not detect RCC lymph neither nodal nor distant metastases and did not show any uptake in the primary renal tumour.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Capitanio U, Pepe G, Incerti E, et al. The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial. Eur J Nucl Med Mol Imaging. 2020. PMID: 32638098. doi:10.1007/s00259-020-04936-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。